LF immunomodulatory strategies: Mastering bacterial endotoxin

Biochemistry and Cell Biology

Volumn 90, Issue 3, 2012, Pages 269-278

  Latorre, Daniela ^a   Berlutti, Francesca ^b   Valenti, Piera ^b   Gessani, Sandra ^a   Puddu, Patrizia ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Immune response; Inflammation; Lactoferrin; Lipopolysaccharide

Indexed keywords

BACTERIAL ENDOTOXINS; BIOLOGICAL FLUIDS; CELLULAR COMPONENTS; COMPLEX INTERACTION; IMMUNE ACTIVATION; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY RESPONSE; INNATE IMMUNE SYSTEMS; IRON BINDING; LACTOFERRIN; LIPOPOLYSACCHARIDES; MOLECULAR BASIS; PROINFLAMMATORY; THERAPEUTIC INTERVENTION; TISSUE DAMAGE;

TISSUE;

MAMMALS;

CHEMOKINE; CYTOKINE; ENDOTOXIN; LACTOFERRIN; LIPOPOLYSACCHARIDE; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4;

AMINO ACID SEQUENCE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; COMPLEX FORMATION; CYTOKINE PRODUCTION; DRUG EFFECT; GLYCOSYLATION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; INNATE IMMUNITY; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; LACTOFERRIN; LIPOPOLYSACCHARIDES; PROTEIN BINDING; TOLL-LIKE RECEPTOR 4;

BACTERIA (MICROORGANISMS); MAMMALIA;

EID: 84861394265     PISSN: 08298211     EISSN: 12086002     Source Type: Journal    
DOI: 10.1139/o11-059     Document Type: Review

References (94)

1. Ando K. Hasegawa K. Shindo K. Furusawa T. Fujino T. Kikugawa K. et al. 2010. Human lactoferrin activates NF-κB through the Toll-like receptor 4 pathway while it interferes with the lipopolysaccharide-stimulated TLR4 signaling. FEBS J. 277 (9): 2051-2066. 10.1111/j.1742-4658.2010.07620.x 20345905
2. Andr J. Lohner K. Blondelle S.E. Jerala R. Moriyon I. Koch M.H. et al. 2005. Enhancement of endotoxin neutralization by coupling of a C12-alkyl chain to a lactoferricin-derived peptide. Biochem. J. 385 (1): 135 - 143. 10.1042/BJ20041270 15344905
3. Appelmelk B.J. An Y.Q. Geerts M. Thijs B.G. de Boer H.A. MacLaren D.M. et al. 1994. Lactoferrin is a lipid A-binding protein. Infect. Immun. 62 (6): 2628-2632. 8188389
4. Artym J. Zimecki M. Kruzel M.L. 2004. Effects of lactoferrin on IL-6 production by peritoneal and alveolar cells in cyclophosphamide-treated mice. J. Chemother. 16 (2): 187-192. 15216955
5. Baker E.N. Anderson B.F. Baker H.M. Day C.L. Haridas M. Norris G.E. et al. 1994. Three-dimensional structure of lactoferrin in various functional states. Adv. Exp. Med. Biol. 357: 1-12. 10.1007/978-1-4615-2548-6-1 7762421
6. Baldi A. Ioannis P. Chiara P. Eleonora F. Roubini C. Vittorio D. 2005. Biological effects of milk proteins and their peptides with emphasis on those related to the gastrointestinal ecosystem. J. Dairy Res. 72 (Suppl. 1): 66-72. 10.1017/S002202990500110X 16180723
7. Baveye S. Elass E. Mazurier J. Legrand D. 2000 a. Lactoferrin inhibits the binding of lipopolysaccharides to L-selectin and subsequent production of reactive oxygen species by neutrophils. FEBS Lett. 469 (1): 5-8. 10.1016/S0014-5793(00)01243-6 10708745
8. Baveye S. Elass E. Fernig D.G. Blanquart C. Mazurier J. Legrand D. 2000 b. Human lactoferrin interacts with soluble CD14 and inhibits expression of endothelial adhesion molecules, E-selectin and ICAM-1, induced by the CD14-lipopolysaccharide complex. Infect. Immun. 68 (12): 6519-6525. 10.1128/IAI.68.12.6519-6525.2000 11083760
9. Berlutti F. Schippa S. Morea C. Sarli S. Perfetto B. Donnarumma G. Valenti P. 2006. Lactoferrin downregulates pro-inflammatory cytokines upexpressed in intestinal epithelial cells infected with invasive or noninvasive Escherichia coli strains. Biochem. Cell Biol. 84 (3): 351-357. 10.1139/o06-039 16936806
10. Beutler B. Rietschel E.T. 2003. Innate immune sensing and its roots: the story of endotoxin. Nat. Rev. Immunol. 3 (2): 169-176. 10.1038/nri1004 12563300
11. Brandenburg K. Kusumoto S. Seydel U. 1997. Conformational studies of synthetic lipid A analogues and partial structures by infrared spectroscopy. Biochim. Biophys. Acta, 1329 (1): 183-201. 10.1016/S0005-2736(97)00109-0 9370256
12. Brandenburg K. Jurgens G. Muller M. Fukuoka S. Koch M.H. 2001. Biophysical characterization of lipopolysaccharide and lipid A inactivation by lactoferrin. Biol. Chem. 382 (8): 1215-1225. 10.1515/BC.2001.152 11592403
13. Brines R.D. Brock J.H. 1983. The effect of trypsin and chymotrypsin on the in vitro antimicrobial and iron-binding properties of lactoferrin in human milk and bovine colostrum. Unusual resistance of human apolactoferrin to proteolytic digestion. Biochim. Biophys. Acta, 759 (3): 229-235. 10.1016/0304-4165(83)90317-3 6349699
14. Britigan B.E. Lewis T.S. Waldschmidt M. McCormick M.L. Krieg A.M. 2001. Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells. J. Immunol. 167 (5): 2921-2928. 11509640
15. Chodaczek G. Zimecki M. Lukasiewicz J. Lugowski C. 2006. A complex of lactoferrin with monophosphoryl lipid A is an efficient adjuvant of the humoral and cellular immune response in mice. Med. Microbiol. Immunol. (Berl.), 195 (4): 207-216. 10.1007/s00430-006-0020-3 16838169
16. Choe Y.-H. Lee S.-W. 2000. Effect of lactoferrin on the production of tumor necrosis factor-alpha and nitric oxide. J. Cell. Biochem. 76 (1): 30-36. 10.1002/(SICI)1097-4644(20000101)76:1<30::AID-JCB4>3.0.CO;2-U 10580998
17. Cohen M.S. Mao J. Rasmussen G.T. Serody J.S. Britigan B.E. 1992. Interaction of lactoferrin and lipopolysaccharide (LPS): effects on the antioxidant property of lactoferrin and the ability of LPS to prime human neutrophils for enhanced superoxide formation. J. Infect. Dis. 166 (6): 1375-1378. 10.1093/infdis/166.6.1375 1331250
18. Conneely O.M. 2001. Antiinflammatory activities of lactoferrin. J. Am. Coll. Nutr. 20 (5 Suppl.): 389S-395S; discussion 396S-397S. 11603648
19. Crichton R.R. 1990. Proteins of iron storage and transport. Adv. Protein Chem. 40: 281-363. 10.1016/S0065-3233(08)60288-0 2195850
20. Crouch S.P. Slater K.J. Fletcher J. 1992. Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin. Blood, 80 (1): 235-240. 1535239
21. Curran C.S. Demick K.P. Mansfield J.M. 2006. Lactoferrin activates macrophages via TLR4-dependent and-independent signaling pathways. Cell. Immunol. 242 (1): 23-30. 10.1016/j.cellimm.2006.08.006 17034774
22. Dawes M.E. Tyler J.W. Marsh A.E. Larson R.L. Steevens B.J. Lakritz J. 2008. In vitro effects of lactoferrin on lipopolysaccharide-induced proliferation, gene expression, and prostanoid production by bovine peripheral blood mononuclear cells. Am. J. Vet. Res. 69 (9): 1164-1170. 10.2460/ajvr.69.9.1164 18764689
23. Elass E. Masson M. Mazurier J. Legrand D. 2002. Lactoferrin inhibits the lipopolysaccharide-induced expression and proteoglycan-binding ability of interleukin-8 in human endothelial cells. Infect. Immun. 70 (4): 1860-1866. 10.1128/IAI.70.4.1860-1866.2002 11895948
24. Elass-Rochard E. Roseanu A. Legrand D. Trif M. Salmon V. Motas C. et al. 1995. Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopolysaccharide. Biochem. J. 312 (3): 839-845. 8554529
25. Elass-Rochard E. Legrand D. Salmon V. Roseanu A. Trif M. Tobias P.S. et al. 1998. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infect. Immun. 66 (2): 486-491. 9453600
26. Ellison R.T. 3rd Giehl T.J. 1991. Killing of Gram-negative bacteria by lactoferrin and lysozyme. J. Clin. Invest. 88 (4): 1080-1091. 10.1172/JCI115407 1918365
27. Groot F. Geijtenbeek T.B. Sanders R.W. Baldwin C.E. Sanchez-Hernandez M. Floris R. et al. 2005. Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN-gp120 interaction. J. Virol. 79 (5): 3009-3015. 10.1128/JVI.79.5.3009-3015.2005 15709021
28. Hamosh M. 1998. Protective function of proteins and lipids in human milk. Biol. Neonate, 74 (2): 163-176. 10.1159/000014021 9691157
29. Haridas M. Anderson B.F. Baker E.N. 1995. Structure of human diferric lactoferrin refined at 2.2 Åresolution. Acta Crystallogr. D Biol. Crystallogr. 51 (5): 629-646. 10.1107/S0907444994013521 15299793
30. HÄversen L. Ohlsson B.G. Hahn-Zoric M. Hanson L.A. Mattsby-Baltzer I. 2002. Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-κ B. Cell. Immunol. 220 (2): 83-95. 10.1016/S0008-8749(03)00006-6 12657243
31. Hayashida K. Kaneko T. Takeuchi T. Shimizu H. Ando K. Harada E. 2004. Oral administration of lactoferrin inhibits inflammation and nociception in rat adjuvant-induced arthritis. J. Vet. Med. Sci. 66 (2): 149-154. 10.1292/jvms.66.149 15031542
32. Heumann D. Roger T. 2002. Initial responses to endotoxins and Gram-negative bacteria. Clin. Chim. Acta, 323 (1-2): 59-72. 10.1016/S0009- 8981(02)00180-8 12135807
33. Ishikado A. Uesaki S. Suido H. Nomura Y. Sumikawa K. Maeda M. et al. 2010. Human trial of liposomal lactoferrin supplementation for periodontal disease. Biol. Pharm. Bull. 33 (10): 1758-1762. 10.1248/bpb.33.1758 20930389
34. Kaito M. Iwasa M. Fujita N. Kobayashi Y. Kojima Y. Ikoma J. et al. 2007. Effect of lactoferrin in patients with chronic hepatitis C: combination therapy with interferon and ribavirin. J. Gastroenterol. Hepatol. 22 (11): 1894-1897. 10.1111/j.1440-1746.2007.04858.x 17914966
35. Kishore A.R. Erdei J. Naidu S.S. Falsen E. Forsgren A. Naidu A.S. 1991. Specific binding of lactoferrin to Aeromonas hydrophila. FEMS Microbiol. Lett. 83 (1): 115-119. 10.1111/j.1574-6968.1991.tb04399.x 1778417
36. Kruzel M.L. Harari Y. Chen C.Y. Castro G.A. 2000. Lactoferrin protects gut mucosal integrity during endotoxemia induced by lipopolysaccharide in mice. Inflammation, 24 (1): 33-44. 10.1023/A:1006935908960 10704062
37. Kruzel M.L. Harari Y. Mailman D. Actor J.K. Zimecki M. 2002. Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice. Clin. Exp. Immunol. 130 (1): 25-31. 10.1046/j.1365-2249.2002.01956.x 12296849
38. Kruzel M.L. Actor J.K. Radak Z. Bacsi A. Saavedra-Molina A. Boldogh I. 2010. Lactoferrin decreases LPS-induced mitochondrial dysfunction in cultured cells and in animal endotoxemia model. Innate Immun. 16 (2): 67-79. 10.1177/1753425909105317 19723832
39. Lee W.J. Farmer J.L. Hilty M. Kim Y.B. 1998. The protective effects of lactoferrin feeding against endotoxin lethal shock in germfree piglets. Infect. Immun. 66 (4): 1421-1426. 9529062
40. Legrand D. Mazurier J. 2010. A critical review of the roles of host lactoferrin in immunity. Biometals, 23 (3): 365-376. 10.1007/s10534-010-9297-1 20143251
41. Legrand D. van Berkel P.H. Salmon V. van Veen H.A. Slomianny M.C. Nuijens J.H. Spik G. 1997. The N-terminal Arg2, Arg3 and Arg4 of human lactoferrin interact with sulphated molecules but not with the receptor present on Jurkat human lymphoblastic T-cells. Biochem. J. 327 (Pt 3): 841-846. 9581564
42. Legrand D. Elass E. Carpentier M. Mazurier J. 2005. Lactoferrin: a modulator of immune and inflammatory responses. Cell. Mol. Life Sci. 62 (22): 2549-2559. 10.1007/s00018-005-5370-2 16261255
43. Legrand D. Pierce A. Elass E. Carpentier M. Mariller C. Mazurier J. 2008. Lactoferrin structure and functions. Adv. Exp. Med. Biol. 606: 163-194. 10.1007/978-0-387-74087-4-6 18183929
44. Leitch E.C. Willcox M.D. 1998. Synergic antistaphylococcal properties of lactoferrin and lysozyme. J. Med. Microbiol. 47 (9): 837-842. 10.1099/00222615-47-9-837 9736166
45. Lu Y.C. Yeh W.C. Ohashi P.S. 2008. LPS/TLR4 signal transduction pathway. Cytokine, 42 (2): 145-151. 10.1016/j.cyto.2008.01.006 18304834
46. Machnicki M. Zimecki M. Zagulski T. 1993. Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin 6 in vivo. Int. J. Exp. Pathol. 74 (5): 433-439. 8217778
47. Mann D.M. Romm E. Migliorini M. 1994. Delineation of the glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin. J. Biol. Chem. 269 (38): 23661-23667. 8089135
48. Mattsby-Baltzer I. Roseanu A. Motas C. Elverfors J. Engberg I. Hanson L.A. 1996. Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells. Pediatr. Res. 40 (2): 257-262. 10.1203/00006450-199608000-00011 8827774
49. Mead P.E. Tweedie J.W. 1990. cDNA and protein sequence of bovine lactoferrin. Nucleic Acids Res. 18 (23): 7167. 10.1093/nar/18.23.7167 2263492
50. Metz-Boutigue M.H. Jolles J. Mazurier J. Schoentgen F. Legrand D. Spik G. et al. 1984. Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. Eur. J. Biochem. 145 (3): 659-676. 10.1111/j.1432-1033.1984.tb08607.x 6510420
51. Mitsuhashi Y. Otsuki K. Yoda A. Shimizu Y. Saito H. Yanaihara T. 2000. Effect of lactoferrin on lipopolysaccharide (LPS) induced preterm delivery in mice. Acta Obstet. Gynecol. Scand. 79 (5): 355-358. 10.1080/j.1600-0412.2000. 079005355.x 10830761
52. Miyazawa K. Mantel C. Lu L. Morrison D.C. Broxmeyer H.E. 1991. Lactoferrin-lipopolysaccharide interactions. Effect on lactoferrin binding to monocyte/macrophage-differentiated HL-60 cells. J. Immunol. 146 (2): 723-729. 1702815
53. Moore S.A. Anderson B.F. Groom C.R. Haridas M. Baker E.N. 1997. Three-dimensional structure of diferric bovine lactoferrin at 2.8 Å resolution. J. Mol. Biol. 274 (2): 222-236. 10.1006/jmbi.1997.1386 9398529
54. Munford R.S. 2005. Detoxifying endotoxin: time, place and person. J. Endotoxin Res. 11 (2): 69-84. 15949133
55. Na Y.J. Han S.B. Kang J.S. Yoon Y.D. Park S.K. Kim H.M. et al. 2004. Lactoferrin works as a new LPS-binding protein in inflammatory activation of macrophages. Int. Immunopharmacol. 4 (9): 1187-1199. 10.1016/j.intimp.2004.05. 009 15251114
56. Naidu S.S. Erdei J. Czirók E. Kalfas S. Gadó I. Thorén A. et al. 1991. Specific binding of lactoferrin to Escherichia coli isolated from human intestinal infections. APMIS, 99 (7-12): 1142-1150. 10.1111/j.1699-0463.1991.tb01311.x 1772651
57. Paesano R. Pietropaoli M. Gessani S. Valenti P. 2009. The influence of lactoferrin, orally administered, on systemic iron homeostasis in pregnant women suffering of iron deficiency and iron deficiency anaemia. Biochimie, 91 (1): 44-51. 10.1016/j.biochi.2008.06.004 18601971
58. Pierce A. Colavizza D. Benaissa M. Maes P. Tartar A. Montreuil J. Spik G. 1991. Molecular cloning and sequence analysis of bovine lactotransferrin. Eur. J. Biochem. 196 (1): 177-184. 10.1111/j.1432-1033.1991.tb15801.x 2001696
59. Puddu P. Carollo M.G. Belardelli F. Valenti P. Gessani S. 2007. Role of endogenous interferon and LPS in the immunomodulatory effects of bovine lactoferrin in murine peritoneal macrophages. J. Leukoc. Biol. 82 (2): 347-353. 10.1189/jlb.1106688 17475783
60. Puddu P. Valenti P. Gessani S. 2009. Immunomodulatory effects of lactoferrin on antigen presenting cells. Biochimie, 91 (1): 11-18. 10.1016/j.biochi.2008.05.005 18539153
61. Puddu P. Latorre D. Valenti P. Gessani S. 2010. Immunoregulatory role of lactoferrin-lipopolysaccharide interactions. Biometals, 23 (3): 387-397. 10.1007/s10534-010-9307-3 20191308
62. Puddu P. Latorre D. Carollo M.G. Catizone A. Ricci G. Valenti P. Gessani S. 2011. Bovine lactoferrin counteracts Toll-like receptor mediated activation signals in antigen presenting cells. PLoS ONE, 6 (7): e22504. 10.1371/journal.pone.0022504 21799877
63. Pugin J. Ulevitch R.J. Tobias P.S. 1993 a. A critical role for monocytes and CD14 in endotoxin-induced endothelial cell activation. J. Exp. Med. 178 (6): 2193-2200. 10.1084/jem.178.6.2193 7504060
64. Pugin J. Schurer-Maly C.C. Leturcq D. Moriarty A. Ulevitch R.J. Tobias P.S. 1993 b. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc. Natl. Acad. Sci. U.S.A. 90 (7): 2744-2748. 10.1073/pnas.90.7.2744 7681988
65. 2+ binding to bovine lactoferrin enhances protein stability and influences the release of bacterial lipopolysaccharide. Biochem. Cell Biol. 80 (1): 41-48. 10.1139/o01-209 11908642
66. Sánchez L. Peiró J.M. Oria R. Castillo H. Brock J.H. Calvo M. 1994. Kinetic parameters for the heat denaturation of bovine lactoferrin in milk, and its effect on interaction with monocytes. Adv. Exp. Med. Biol. 357: 253-257. 10.1007/978-1-4615-2548-6-27 7762440
67. Sasaki Y. Otsuki K. Hasegawa A. Sawada M. Chiba H. Negishi M. et al. 2004. Preventive effect of recombinant human lactoferrin on lipopolysaccharide- induced preterm delivery in mice. Acta Obstet. Gynecol. Scand. 83 (11): 1035-1038. 15488117
68. Schromm A.B. Brandenburg K. Loppnow H. Moran A.P. Koch M.H. Rietschel E.T. Seydel U. 2000. Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion. Eur. J. Biochem. 267 (7): 2008-2013. 10.1046/j.1432-1327.2000.01204.x 10727940
69. Schumann R.R. Leong S.R. Flaggs G.W. Gray P.W. Wright S.D. Mathison J.C. et al. 1990. Structure and function of lipopolysaccharide binding protein. Science, 249 (4975): 1429-1431. 10.1126/science.2402637 2402637
70. Shimazu R. Akashi S. Ogata H. Nagai Y. Fukudome K. Miyake K. Kimoto M. 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189 (11): 1777-1782. 10.1084/jem.189.11.1777 10359581
71. Spik G. Coddeville B. Montreuil J. 1988. Comparative study of the primary structures of sero-, lacto-and ovotransferrin glycans from different species. Biochimie, 70 (11): 1459-1469. 10.1016/0300-9084(88)90283-0 3149515
72. Talukder M.J. Harada E. 2007. Bovine lactoferrin protects lipopolysaccharide-induced diarrhea modulating nitric oxide and prostaglandin E2 in mice. Can. J. Physiol. Pharmacol. 85 (2): 200-208. 10.1139/Y07-004 17487261
73. Tian H. Maddox I.S. Ferguson L.R. Shu Q. 2010. Evaluation of the cytoprotective effects of bovine lactoferrin against intestinal toxins using cellular model systems. Biometals, 23 (3): 589-592. 10.1007/s10534-010-9301-9 20157763
74. Tomita M. Wakabayashi H. Shin K. Yamauchi K. Yaeshima T. Iwatsuki K. 2009. Twenty-five years of research on bovine lactoferrin applications. Biochimie, 91 (1): 52-57. 10.1016/j.biochi.2008.05.021 18585434
75. Tsuda H. Kozu T. Iinuma G. Ohashi Y. Saito Y. Saito D. et al. 2010. Cancer prevention by bovine lactoferrin: from animal studies to human trial. Biometals, 23 (3): 399-409. 10.1007/s10534-010-9331-3 20407806
76. Tursi A. Elisei W. Brandimarte G. Giorgetti G.M. Modeo M.E. Aiello F. 2007. Effect of lactoferrin supplementation on the effectiveness and tolerability of a 7-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. Med. Sci. Monit. 13 (4): CR187-CR190. 17392649
77. Valenti P. Antonini G. 2005. Lactoferrin: an important host defence against microbial and viral attack. Cell. Mol. Life Sci. 62 (22): 2576-2587. 10.1007/s00018-005-5372-0 16261253
78. van Veen H.A. Geerts M.E. van Berkel P.H. Nuijens J.H. 2004. The role of N-linked glycosylation in the protection of human and bovine lactoferrin against tryptic proteolysis. Eur. J. Biochem. 271 (4): 678-684. 10.1111/j.1432-1033. 2003.03965.x 14764083
79. Viani R.M. Gutteberg T.J. Lathey J.L. Spector S.A. 1999. Lactoferrin inhibits HIV-1 replication in vitro and exhibits synergy when combined with zidovudine. AIDS, 13 (10): 1273-1274. 10.1097/00002030-199907090-00018 10416533
80. Wang C.S. Chan W.Y. Kloer H.U. 1984. Comparative studies on the chemical and immunochemical properties of human milk, human pancreatic juice and bovine milk lactoferrin. Comp. Biochem. Physiol. B, 78 (3): 575-580. 10.1016/0305-0491(84)90100-7 6434227
81. Wang D. Pabst K.M. Aida Y. Pabst M.J. 1995. Lipopolysaccharide- inactivating activity of neutrophils is due to lactoferrin. J. Leukoc. Biol. 57 (6): 865-874. 7790769
82. Ward P.P. Paz E. Conneely O.M. 2005. Multifunctional roles of lactoferrin: a critical overview. Cell. Mol. Life Sci. 62 (22): 2540-2548. 10.1007/s00018-005-5369-8 16261256
83. Wei Z. Nishimura T. Yoshida S. 2000. Presence of a glycan at a potential N-glycosylation site, Asn-281, of bovine lactoferrin. J. Dairy Sci. 83 (4): 683-689. 10.3168/jds.S0022-0302(00)74929-0 10791783
84. Westphal O. Luderitz O. Rietschel E.T. Galanos C. 1981. Bacterial lipopolysaccharide and its lipid A component: some historical and some current aspects. Biochem. Soc. Trans. 9 (3): 191-195. 7274542
85. Wright S.D. 1995. CD14 and innate recognition of bacteria. J. Immunol. 155 (1): 6-8. 7541427
86. Wright S.D. Ramos R.A. Tobias P.S. Ulevitch R.J. Mathison J.C. 1990. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science, 249 (4975): 1431-1433. 10.1126/science.1698311 1698311
87. Wu H.F. Monroe D.M. Church F.C. 1995. Characterization of the glycosaminoglycan-binding region of lactoferrin. Arch. Biochem. Biophys. 317 (1): 85-92. 10.1006/abbi.1995.1139 7872808
88. Yajima M. Yajima T. Kuwata T. 2005. Intraperitoneal injection of lactoferrin ameliorates severe albumin extravasation and neutrophilia in LPS-induced inflammation in neonatal rats. Biomed. Res. 26 (6): 249-255. 10.2220/biomedres.26.249 16415506
89. Yamaguchi M. Matsuura M. Kobayashi K. Sasaki H. Yajima T. Kuwata T. 2001. Lactoferrin protects against development of hepatitis caused by sensitization of Kupffer cells by lipopolysaccharide. Clin. Diagn. Lab. Immunol. 8 (6): 1234-1239. 11687469
90. Yamano E. Miyauchi M. Furusyo H. Kawazoe A. Ishikado A. Makino T. et al. 2010. Inhibitory effects of orally administrated liposomal bovine lactoferrin on the LPS-induced osteoclastogenesis. Lab. Invest. 90 (8): 1236-1246. 10.1038/labinvest.2010.80 20421871
91. Yeom M. Park J. Lee B. Choi S.Y. Kim K.S. Lee H. Hahm D.H. 2011. Lactoferrin inhibits the inflammatory and angiogenic activation of bovine aortic endothelial cells. Inflamm. Res. 60 (5): 475-482. 10.1007/s00011-010-0294-1 21161563
92. Yoshida S. Wei Z. Shinmura Y. Fukunaga N. 2000. Separation of lactoferrin- A and-b from bovine colostrum. J. Dairy Sci. 83 (10): 2211-2215. 10.3168/jds.S0022-0302(00)75104-6 11049060
93. Zagulski T. Lipinski P. Zagulska A. Broniek S. Jarzabek Z. 1989. Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo. Br. J. Exp. Pathol. 70 (6): 697-704. 2690922
94. Zhang G.H. Mann D.M. Tsai C.M. 1999. Neutralization of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide. Infect. Immun. 67 (3): 1353-1358. 10024582